Zeposia (Ozanimod Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Zeposia (Ozanimod Hydrochloride) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2038-09-30, 0 AB generics, $146.4M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN209899 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-09-30
Last Listed Patent or Exclusivity Date2038-09-30
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$146.4M
2024 Medicare Part D Spend$91.0M
2024 Medicaid Spend$55.4M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 20.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.